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Abstract: Various studies have demonstrated the safety and efﬁ  cacy of recombinant human 
thyroid-stimulating hormone (rhTSH) for radioiodine remnant ablation. On this basis, rhTSH was 
approved in Europe for the radioiodine ablation of low-risk differentiated thyroid cancer (DTC) 
during thyroid hormone therapy with L-thyroxine (L-T4). Moreover, in December 2007, the US 
Federal Drug Administration approved the use of rhTSH for adjuvant treatment with radioiodine 
in patients with DTC without evidence of metastatic thyroid cancer. Quality of life was found to 
be better with rhTSH preparation than with L-thyroxine withdrawal, thereby resulting in beneﬁ  ts 
for society as a whole. Furthermore, rhTSH for radioiodine remnant ablation results in a longer 
effective radioiodine half-life within remnant thyroid tissue and a lower speciﬁ  c absorbed dose 
in the blood and exposure of bone marrow to X-rays. More studies are required to establish the 
amount of radioiodine to be administered especially in high-risk patients.
Keywords: thyroid cancer, thyrotropin, radioiodine (131I) remnant ablation (RRA), quality of 
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There is general agreement that total thyroidectomy is the initial treatment-of-choice for 
patients with differentiated thyroid cancer (DTC).1,2 Radioiodine (131I) remnant ablation 
is recommended after thyroidectomy to destroy post-surgical residual thyroid tissue 
especially in patients at high-risk of recurrence and mortality.1,2 131I ablation has two 
advantages: 1) it destroys any remaining microscopic tumoral foci; and 2) it eliminates 
all normal thyroid cells that would continue to produce thyroglobulin and confound 
interpretation of measurement of serum thyroglobulin (Tg), which is a speciﬁ  c marker 
of recurrent or persistent disease. Consequently, this procedure improves the follow-up 
and treatment of patients with DTC by increasing the speciﬁ  city and sensitivity of Tg 
monitoring and 131I treatment. Moreover, 131I administration decreases the frequency 
of recurrences and mortality.3–6
Elevated serum thyroid-stimulating hormone (TSH) levels (above 30 mU/L) are 
necessary to ensure sufﬁ  cient trapping and retention of 131I by functioning thyroid 
tissue.1 Traditionally, the endogenous increase of TSH was achieved by withdrawal 
of thyroid hormone therapy (L-thyroxine; LT4) for 4 to 5 weeks, which induces 
clinical hypothyroidism. However, this short-term hypothyroid condition is associated 
with cognitive and physical impairment and alteration of quality of life in young and 
middle-aged patients.7,8 Moreover, withdrawal of LT4 can impair cardiac, cognitive 
and neurological function with consequent health risks especially for elderly people.7,8 
Lastly, it may not increase TSH levels in cases of persistent thyroid hormone produc-
tion by large thyroid remnants or functional metastases, in elderly patients, and in the 
presence of hypothalamic or pituitary disease or long-term steroid therapy.9–12
Recombinant human TSH (rhTSH) is a heterodimeric glycoprotein produced by 
recombinant DNA technology for the purpose of producing increased TSH levels without Biologics: Targets & Therapy 2009:3 10
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LT4 withdrawal and the consequent hypothyroidism. The use 
of rhTSH was initially limited to the ﬁ  eld of DTC follow-up 
and was approved by the US Food and Drug Administration 
(FDA) in December 1998 for diagnostic use. Subsequently, 
rhTSH was found to be effective for 131I remnant ablation,13,14 
and in February 2005, rhTSH was approved in Europe for the 
131I ablation of low-risk DTC during thyroid hormone therapy 
with LT4. In December 2007 the FDA approved the use of 
rhTSH for adjuvant treatment with 131I in patients with DTC 
without evidence of metastatic thyroid cancer.
Here we review the studies on rhTSH-aided ablation 
with the aim of addressing such open questions as the exact 
protocol of rhTSH administration and the dose of 131I to obtain 
maximum effectiveness.
RhTSH-aided ablation: 
literature analysis
Table 1 lists the studies that evaluated the effectiveness of 
rhTSH in the adjuvant treatment for 131I remnant ablation in 
DTC patients. The criteria used to deﬁ  ne successful thyroid 
ablation differed among studies from no visible uptake at whole 
body scan after rhTSH or undetectable basal and rhTSH-stimu-
lated serum thyroglobulin. Despite these differences, there is 
general agreement that rhTSH for thyroid ablation gives results 
similar to those found after LT4 withdrawal.
The study by Perros et al was the ﬁ  rst report on the use of 
rhTSH to increase 131I uptake for remnant ablation.15 Subse-
quently, the effect of rhTSH-aided ablation was evaluated in a 
prospective non-randomized trial of 10 patients with papillary 
cancer.16 The dose of 131I administrated varied between 30 and 
250 mCi. The ablation rate was 100% when judged by the 
absence of visible uptake in the thyroid bed after diagnostic 
whole body scan 3 months after ablation.16 Another random-
ized study conﬁ  rmed complete ablation after high doses 
of 131I (approximately 108 mCi) by using TSH to stimulate 
131I uptake for the ablation of remnant thyroid tissue.17
A subsequent retrospective study from the Memorial Sloan-
Kettering Cancer Center conﬁ  rmed that a high dose of 131I 
increased the rate of rhTSH-aided ablation in DTC patients.13 In 
this study, the rates of complete ablation did not differ signiﬁ  -
cantly between a group of patients who were prepared by thyroid 
hormone withdrawal (THW) and a group of patients prepared 
by rhTSH when treated with 100 mCi (84% in 45 euthyroid 
patients after rhTSH vs 81% in 42 hypothyroid patients)13.
However, a prospective study by Pacini et al did not 
conﬁ  rm these results.18 In this prospective randomized study 
in which 1.1 GBq (30 mCi) was used as standard ablative 
activity, 162 DTC patients were randomized in three treat-
ment arms: in the ﬁ  rst arm, patients (n = 50) were treated 
by LT4 withdrawal (HYPO); in the second arm, patients 
Table 1 Studies evaluating the efﬁ  cacy of rhTSH for remnant ablation
Authors  Patients (n)  Stage of disease Dose of 131I (mCi) Outcome
rhTSH LT4W rhTSH LT4W rhTSH LT4W rhTSH LT4W
Robbins et al 2001
Prospective 
randomized study
10 n.p. T1–T4 n.p. 30–250 n.p.
100% dWBS negative,
60% Tg < 1.0
Pacini et al 2002
Prospective 
randomized study 
70 50 T1–T4 
N0–N1
T1–T4 
N0–N1
30 30 54% dWBS negative 
86,8% Tg < 1.0
84% dWBS negative 
83% Tg < 1.0
42 rhTSH + 
LT4Wl
T1–T4 
N0–N1
30 78.5% dWBS negative 
84.8% Tg < 1.0
Robbins et al 2002
Retrospective study 
45 42 T1–T4 
N0–N1
T1–T4 
N0–N1
110.4 ± 65  128.9 ± 74  81% dWBS negative  84% dWBS negative 
Barbaro et al 2003
Non-randomized 
prospective study 
16 19 1–2 1–2 30 30 77% dWBS negative 
86.5% Tg < 1.0
76% dWBS negative 
76 % Tg < 1.0
Pacini et al 2006
Prospective 
randomized study 
33 30 T1–T4 
N0–N1
T1–T4
N0–N1
100 100 75% dWBS negative 
96% Tg < 2.0
86% dWBS negative
86% Tg < 2.0
Pilli et al 2007
Prospective 
randomized study 
36 n.p. T1–T4 
N0–N1
T1–T4
N0–N1
50 n.p. 88.9 % dWBS negative 
78.9% Tg < 1.0
36 T1–T4 
N0–N1
T1–T4
N0–N1
100 n.p. 88.9% dWBS negative 
67% Tg < 1.0
n.p. = not performed.
Abbreviations: rhTSH, recombinant human thyroid-stimulating hormone; dWBS, diagnostic whole body scanner; LT4W, levo-thyroxine withdrawal; Tg, serum thyroglobulin.Biologics: Targets & Therapy 2009:3 11
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(n = 42) were treated by LT4 withdrawal combined with 
rhTSH (HYPO + rhTSH); in the third arm, patients (n = 70) 
were stimulated with rhTSH in euthyroidism (EU + rhTSH). 
The follow-up was performed 6 to 10 months post ablation. 
When the criterion for successful ablation was no uptake 
on the thyroid bed on diagnostic whole body scan, the 
rate of successful ablation was similar in the HYPO and 
HYPO + rhTSH groups (84% and 78.5%, respectively) 
but signiﬁ  cantly lower (54% p  0.01) in the EU + rhTSH 
group.18 On the contrary when successful ablation was 
deﬁ  ned as no visible thyroid bed uptake on diagnostic whole 
body scan or undetectable serum Tg after rhTSH, the success 
rates were similar (95% vs 74%). However, the reduced rate 
of ablation in the EU group may be explained by the protocol 
of 131I administration used by Pacini et al.18 Indeed, ablative 
131I administration was delayed by 24 h and it was delivered 
48 h after the second injection of rhTSH. Therefore, the 
authors suggested that the dose of 131I be increased or that 
different protocols of rhTSH administration be used to obtain 
a satisfactory rate of rhTSH-aided thyroid ablation.
An international randomized controlled trial showed that 
the efﬁ  cacy of rhTSH for ablation was similar to that of LT4 
withdrawal with 100% ablation after 3.7 GBq (100 mCi).14 The 
predeﬁ  ned primary criterion for successful ablation was “no 
visible uptake in the thyroid bed, or a visible uptake less than 
0.1%” on neck scans performed 8 months after therapy, and 
was satisﬁ  ed in 100% of patients in both groups. A secondary 
criterion for ablation, a rhTSH-stimulated serum thyroglobulin 
concentration less than 2 ng/mL, was fulﬁ  lled by 23 of 24 
(96%) euthyroid rhTSH patients and 18 of 21 (86%) hypo-
thyroid patients (p = 0.2341). In this randomized prospective 
ablation trial, all rhTSH patients had an iodine excretion below 
200 µ/L, indicating the absence of overt iodine excess.
Only two studies have evaluated the efﬁ  cacy of rhTSH for 
remnant ablation with lower 131I doses.19,20 A recent study by 
Pilli et al showed that 1850 MBq (50 mCi) 131I had a similar 
success rate to 3700 MBq (100 mCi) in 72 patients prepared 
with rhTSH for thyroid ablation.19 This prospective, random-
ized study showed that 3700 MBq 131I is associated with high 
rates of successful thyroid ablation after rhTSH preparation 
and that similar ablation rates (88.9%) were obtained with 
lower 131I activity (1850 MBq). These results were obtained 
when the criterion of  successful ablation was deﬁ  ned as no vis-
ible uptake at the 6- to 8-month control diagnostic 131I whole 
body scan after rhTSH stimulation, and also when the 
criterion of successful ablation was undetectable (1 ng/mL) 
rhTSH-stimulated serum Tg. Furthermore, successful 
ablation was also obtained in patients with nodal metastases. 
Lastly, the dosimetric study showed that thyroid uptake was 
similar in patients treated with 1850 or 3700 MBq.
Since thyroid hormones are an important source of iodine 
and may interfere with 131I uptake during thyroid ablation, 
Barbaro et al suggested LT4 therapy be discontinued before 
rhTSH injection.20 They compared ablation obtained with 
doses of 30 mCi in 2 groups of DTC patients: one group was 
prepared by hypothyroidism and the other group was prepared 
by rhTSH stimulation. In the rhTSH group, LT4 therapy was 
interrupted for 4 days starting the day before the ﬁ  rst injection. 
In the rhTSH group, urinary iodine excretion was signiﬁ  cantly 
lower than in a control group of euthyroid subjects who receci-
ved rhTSH stimulation. One year later, patients underwent a 
whole body scan with a tracer dose of 131I and serum Tg was 
measured using rhTSH with the same protocol in both groups. 
The percentage of ablation (undetectable Tg and a negative 
whole body scan) was 81.2% in patients treated with rhTSH 
and 76% in patients treated by L-T4 withdrawal.
Similarly, Pitoia et al suggested replacing LT4 with LT3 
therapy to maintain the euthyroid state and to minimize the 
iodine pool during rhTSH preparation.21 Indeed, LT3 has an 
iodine content 5-fold less than LT4.21
RhTSH-aided ablation: 131I dosimetry, 
safety and cost
Because  131I activity is associated with such important risks 
as bone marrow depression and pulmonary ﬁ  brosis, several 
dosimetric studies have been performed to evaluate the absorbed 
dose in the blood (a surrogate for bone marrow) and 131I activity 
in the lung to determine the minimum effective dose to reduce 
the these risks. It has been reported that a dose of 2 Gy of radia-
tion in the blood is dose-limiting,22 whereas 3 GBq in the lung 
in 24 h is the safety limit to avoid pulmonary ﬁ  brosis.23
An international, prospective, randomized study compared 
the iodine biokinetics, dosimetry and the effectiveness of abla-
tion therapy with 100 mCi in DTC after rhTSH stimulation 
or LT4 withdrawal.24 Iodine biokinetics differed between the 
two groups of patients.24 In fact, in the euthyroid state, renal 
clearance of iodine was 50% faster than in hypothyroidism.31 
Indeed, fractional 131I uptake into thyroid remnants was lower 
after rhTSH stimulation than after LT4 withdrawal.24 However, 
this reduction was partially compensated for by an increased 
half-life of 131I in thyroid cells after rhTSH stimulation.24 
rhTSH-treated patients showed a longer effective 131I half-life 
within remnant thyroid tissue, and the residence times of the 
radioisotope were comparable in the two groups.24 Moreover, 
the speciﬁ  c absorbed dose in the blood was signiﬁ  cantly 
lower (one-third) after rhTSH preparation, suggesting that Biologics: Targets & Therapy 2009:3 12
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higher  131I activities might be safely administered after 
rhTSH stimulation.24 Finally, another study conﬁ  rmed that 
the bone marrow absorbed dose remained under 2 Gy after 
rhTSH-aided administration of high activities of 131I.25 More-
over, patients prepared with rhTSH had a better quality of 
life than hypothyroid patients.14,29,30 RhTSH-aided ablation 
was well tolerated with no important side effects, and it can 
be useful in elderly patients and in patients with associated 
co-morbidities without increasing the risk of cardiac, cerebro-
vascular, pulmonary or neurological complications.8,26,27
Finally, a recent study compared the cost-effectiveness 
of ablation after rhTSH stimulation or LT4 withdrawal. The 
additional cost of rhTSH procurement and administration 
was considered justiﬁ  ed in relation to the clinical beneﬁ  ts and 
cost offsets such as avoidance of hypothyroidism, increased 
work productivity and quality life, reduced discharge from 
radioprotection and period of sick leave.28 These observations 
were recently conﬁ  rmed by Borget et al30 who found that 
rhTSH can decrease the duration of sick leave, and that 
its high cost is compensated for by beneﬁ  ts to patients and 
society with a modest net cost.30
RhTSH-aided ablation: advantages 
and limits
There is general agreement that rhTSH-aided ablation is 
effective and safe. Various studies have conﬁ  rmed the efﬁ  cacy 
of rhTSH in aiding ablation and show that rhTSH preparation 
is more beneﬁ  cial than LT4 withdrawal32 in terms of quality of 
life1,4,29,30 and well-being and avoids the important side effects 
of short-term hypothyroidism. Moreover, rhTSH for remnant 
ablation decreases exposure of bone marrow to X-rays.
Several questions are still open, namely, the amount of 
131I to be administered and the effect of iodine intake. More 
studies are required to evaluate whether rhTSH can be used 
effectively for remnant ablation in high risk patients with 
outcomes at least comparable to those seen with ablation 
after thyroxine withdrawal.
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